Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Jun

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Immunotherapy With Cemiplimab-rwlc Yields Survival Benefit in Advanced Cervical Cancer

Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma

Are There Differences in the Prevalence of Germline Pathogenic Variants in Susceptibility Genes in Black vs White Women With Breast Cancer

Pembrolizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer KEYNOTE-057

Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer